Celtrix Pharmaceuticals, Inc.

Bioexpertise LLC

Ontherix, Inc.

Protigen, Inc.

Other

Celtrix Phamraceuticals, Inc.

Desmond D Mascarenhas

Pamela S Olson

David R Olsen

Yang Zhang

Pedro A Carrillo

Pedro A Cohen

Martin Sanders

James R Dasch

Stephen Danko

David Passmore

Patricia R Segarini

Kimyen B Nguyen

Stress, such as from physical, metabolic or psychological trauma, is associated with enduring secondary complications leading to morbidity and/or death in subjects that receive the stress insult. The epigenetic oxidative stress response to a stress insult is characterized by (a) global epigenetic events such as changes in DNA methylation and phosphorylation of Ser10 and acetylation of Lys9/14 residues of histone-3 (b) significant systemic elevations in analytes of oxidative stress in body fluids such as blood or urine and (c) deterioration of clinically relevant parameters such as glycemic control, organ function, lean body mass and rate of healing. The applicant teaches a method of counteracting the grave systemic effects of stress insult with reference to the epigenetic oxidative stress response, by daily subcutaneous bolus injections of nephrilin peptide beginning soon after insult and continuing for seven days. These methods of combating epigenetic oxidative stress response are new and have not been described in the prior art. Specifically, the use of nephrilin (acting on its target, Rictor complex) to obviate the epigenetic changes in trauma that result in systemic oxidative stress, is new. Previously disclosed work on nephrilin had not described its effects on epigenetic change (mechanism) or oxidative stress (readout). The relevance of this particular epigenetic-oxidative-stress cascade to clinically relevant outcomes such as loss of organ function, glycemic control or lean body mass was unknown, as was the use of nephrilin molecule to counteract these phenomena. The invention relates to the use of specific therapeutic agents such as nephrilin to ameliorate the epigenetic oxidative stress response, and specifically the above-mentioned clinically relevant parameters.

Modulation of epigenetic stress response

The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.

Adaptive biochemical signatures

A computer-implemented system for creating a classification significance pattern for end users, and enabling end users to use their classification significance pattern to conduct custom searches for target information, such as information about products, services, and jobs, as well as enabling third parties, such as vendors and potential employers, to target their advertisements to groups of users meeting a certain classification. A classification significance pattern is created by having a user take a psychological test, for example, that includes a personality test, a design taste test, a recreation/travel test, a life satisfaction test, an interactive game module, or a career/job test, and having the system automatically score such test and classifying the user based on a defined abstract classification.

System and method for using psychological significance pattern information for matching with target information

The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.

Metal-binding therapeutic peptides

New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

Method for use of IGF-binding protein for selective sensitization of target cells in vivo

New methods for the treatment of cancer are provided. Null IGF (IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer.

Null IGF for the treatment of cancer

This invention relates generally to a computer-implemented method and system for having anonymous profiling of, and marketing to, anonymous users in a data network, particularly in the Internet. It enables an individual to surf the Internet anonymously as well as enabling third parties to use profiling information to target such anonymous users. The real identity of the individual is never known within the anonymous trust system.

System and method for anonymous transaction in a data network and classification of individuals without knowing their real identity

The present invention provides a system and method for creating and maintaining a Biomedical document database, wherein the documents have been reviewed by biomedical and other experts, who have assigned taxonomic based indicia to each document wherein a specialized search engine can rapidly retrieve relevant documents based upon the commnly known taxonomy.

Computer implemented searching using search criteria comprised of ratings prepared by leading practitioners in biomedical specialties

New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.

IGF-binding protein-derived peptide or small molecule

IGF-binding protein-derived peptide

The present invention provides a method, system, and computer product to evaluate a user's learning style. The user is presented with a series of interactive assessment exercises, wherein each exercise contains one or more clues, a number of correct cards, and a number of incorrect cards. The user's responses, which include the types and number of moves made, the time it takes to select another card, and the like are received, recorded, or captured. Based on the user's responses, the responses are evaluated and used in a learning style formula to determine the learning style of a user. The invention also provides for a method, system, and computer product that evaluate a user's comprehension of a certain topic or subject matter. The user is presented with an interactive assessment exercise, wherein such exercise contains one or more clues, a number of correct cards, and a number of incorrect cards.

Growing community of inventors

Auburn, CA, United States of America

Desmond D Mascarenhas